Kigabeq
·
- Prescription status not stated
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Vigabatrin
- Made by
- Orphelia Pharma S.A.S.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for: Treatment in monotherapy of infantile spasms (West's syndrome). Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Orphelia Pharma S.A.S. |
|---|---|
| Active substance | Vigabatrin |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Classification | N03AG04 · Pain, sleep, mood, epilepsy and the brain |
| Authorised on | 2018-09-20 |
| Last updated by the regulator | 2026-07-22 |
| EMA product number | EMEA/H/C/004534 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).